Rapport Therapeutics Announces That Topline Results From Its Phase 2 Trial Of RAP-219 In Adults With Acute Bipolar Mania Met Primary Endpoint

Rapport Therapeutics announced that its Phase 2 trial of RAP-219 in adults with acute bipolar mania met both primary and secondary endpoints, showing statistically significant improvements in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania score (0.4 points; p=0.024) at Week 3. Patients treated with RAP-219 experienced a mean reduction of 15.4 points in the YMRS total score from baseline. The treatment was well tolerated, with all adverse events being mild or moderate. The company will host a conference call today at 8:00 a.m. ET.